{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-202366","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.499095+00:00","generated_at":"2026-05-17T06:43:20.131883+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam issues $661.25M zero-coupon convertible notes due 2028; repurchases $637.8M of existing notes","bullets":["Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).","Capped call transactions entered to offset dilution; cost $35.3M, cap price $837.61/share (~75% premium).","Repurchased $637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M total (including accrued interest).","Notes mature Sept 15, 2028, no regular interest; settlement in cash, shares, or combination at Alnylam's election."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-202366","json":"https://secwatch.observer/filing/0001193125-25-202366.json","markdown":"https://secwatch.observer/filing/0001193125-25-202366.md","text":"https://secwatch.observer/filing/0001193125-25-202366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/0001193125-25-202366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/d949176d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:43:20.131883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f635b8e353f4268040093080cca0eaf085a14f26","claim":"ALNYLAM PHARMACEUTICALS, INC. incurred convertible notes of $661.25 million with The Bank of New York Mellon at 0.00% maturing September 15, 2028.","evidence_excerpt":"0.00% Convertible Senior Notes due 2028 (the “Additional Notes” and together with the Initial Notes, the “Notes”), bringing the total aggregate principal amount of the Notes to $661.25 million. The Notes are the Company’s senior unsecured obligations. The Notes were issued pursuant to an Indenture, dated September 12, 2025 (the “Indenture”), between the Company and The","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/0001193125-25-202366-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$661.25 million"},{"label":"Counterparty","value":"The Bank of New York Mellon"},{"label":"Rate","value":"0.00%"},{"label":"Maturity","value":"September 15, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}